| answer text |
<p>SecurMed, the not-for-profit company set up by stakeholders in the United Kingdom
medicines supply chain, is responsible for setting the fee model and level of fees
as the UK’s National Medicines Verification Organisation (NMVO). In their supervisory
capacity, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Department’s
aim is to ensure that SecurMed is complying with the regulation in a fair and proportionate
way. As part of that role, the MHRA and the Department have been involved in discussions
with SecurMed to challenge and seek to influence the pricing model to ensure that
the UK’s fee structure is fair and proportionate.</p><p> </p><p>The European Commission
has confirmed that the fee model being used by SecurMed is in line with the majority
of other member states NMVO’s across the European Union. It is based on the number
of users and cost per connection where larger organisations, which are more likely
to have multiple marketing authorisations, pay more. An annual fee waiver scheme exists
for micro Marketing Authorisation Holders which is designed to support start-ups and
help ensure there is not a barrier to market entry.</p>
|
|
